| Date | Title | Description | Source |
| 17.01.2013 | NuPathe gets FDA approval for migraine patch | The approval for the Zecuity came more than a year after the Conshohocken, Pennsylvania-based compan... | medcitynew... |
| 13.11.2012 | Penn (still) has high rate of alumni entrepreneurs leaving t... | Welcome to the VC Roundup, where we’ll parse through venture capital news related to Philadelphia-ba... | technical.... |
| 30.10.2012 | Safeguard Scientifics sees lower valuations, bigger 3Q loss ... | Welcome to the VC Roundup, where we’ll parse through venture capital news related to Philadelphia-ba... | technical.... |
| 30.10.2012 | Safeguard Scientifics sees lower valuations, bigger 3Q loss ... | Welcome to the VC Roundup, where we’ll parse through venture capital news related to Philadelphia-ba... | technical.... |
| 09.10.2012 | Migraine patch developer reduces workforce in cost cutting m... | Anido replaced Jane Hollingsworth, who started the company in 2006, and had previously suceeded her ... | medcitynew... |
| 26.09.2012 | Migraine pain patch developer NuPathe raises $28M in private... | Armando Anido, the CEO of the company who replaced Jane Hollingsworth earlier this year, said in a s... | medcitynew... |
| 26.09.2012 | Abiomed: Medicare coverage decision unlikely for Impella | W... | Abiomed (NSDQ:ABMD) said it doesn’t believe that the Centers for Medicare & Medicaid Services is... | massdevice... |
| 26.07.2012 | Migraine patch developer’s new CEO maps out priorities for c... | “My number one priority is cash. We need to have sufficient resources from a money standpoint to exe... | medcitynew... |
| 25.07.2012 | Biopharmaceutical firm NuPathe co-founder and CEO exits, ent... | Incoming CEO and board member Armando Anido has 30 years of experience in the pharmaceutical industr... | medcitynew... |
| 16.07.2012 | Migraine patch application resubmitted for FDA approval | Jane Hollingsworth, NuPathe’s CEO, said she expects a six-month review by the FDA.
“With the additi... | medcitynew... |
| 19.12.2011 | NuPathe CEO on leading a startup and the challenge of shifti... | Six years after NuPathe’s launch to develop drugs for central nervous system disorders from migraine... | medcitynew... |
| 29.11.2011 | NB Therapeutics raising $1 million to fund nail fungus thera... | Iontophoresis involves using electric currents to improve drug delivery through the skin and nails, ... | medcitynew... |
| 15.11.2011 | NuPathe to resubmit migraine patch for approval in 2012 | Migraine headaches affect about 31 million adults in the United States. Symptoms include moderate to... | medcitynew... |
| 21.02.2011 | New Pittsburgh venture fund eyes Cleveland location | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Hea... | medcitynew... |
| 18.09.2009 | Friday Q&A: Jane Hollingsworth of NuPathe on Zelrix, mig... | Updated 9/18/09 @ 2:42 p.m. Name in title
When Jane Hollingsworth takes a pill to help fight a head... | technical.... |
| 07.08.2009 | Friday Q&A: Russell Greig of GlaxoSmithKline’s SR One... | Russell Greig has come a long way.
The 57-year-old Scotsman, who still carries that signature and r... | technical.... |
| - | NuPathe CEO on leading a startup and the challenge of shifti... | Jane Hollingsworth, the CEO of NuPathe (NASDAQ:PATH), tends to stand out around Philadelphia. It’s n... | medcitynew... |
| - | NuPathe to resubmit migraine patch for approval in 2012 | NuPathe (NASDAQ: PATH) said it will resubmit a new drug application for its transdermal migraine pat... | medcitynew... |
| - | New Pittsburgh venture fund eyes Cleveland location | A newly created venture capital fund from Pittsburgh may be coming to Northeast Ohio — if it can hit... | medcitynew... |
| - | NuPathe gets FDA approval for migraine patch | Migraine sufferers (and no doubt some investors) will be feeling some relief tonight after NuPathe (... | medcitynew... |
| - | Migraine patch developer reduces workforce in cost cutting m... | The new CEO of NuPathe (NASDAQ:PATH) followed through on his pledge to cut costs at the biopharmaceu... | medcitynew... |
| - | NB Therapeutics raising $1 million to fund nail fungus thera... | Nitric BioTheraputics, a biopharmaceutical and medical device company, is raising $1 million to fund... | medcitynew... |
| - | Migraine patch developer’s new CEO maps out priorities for c... | The leadership change at NuPathe (NASDAQ:PATH) has ushered in a CEO with the sales and marketing bac... | medcitynew... |
| - | Migraine pain patch developer NuPathe raises $28M in private... | In the run up to the commercialization of its migraine pain patch drug delivery system, NuPathe (NAS... | medcitynew... |
| - | Migraine patch application resubmitted for FDA approval | NuPathe (NASDAQ:PATH), a biopharmaceutical company, has resubmitted a new drug application for its m... | medcitynew... |
| - | Biopharmaceutical firm NuPathe co-founder and CEO exits, ent... | Biopharmaceutical firm NuPathe’s (NASDAQ:PATH) CEO Jane Hollingsworth has resigned as CEO and board ... | medcitynew... |
